Characterization of Prescription Opioid Abuse in the United States: Focus on Route of Administration

REFERENCES

• American Pain Society, National Pharmaceutical Council. Pain: current understanding of assessment, management, and treatments. Glenview, IL: American Pain Society; 2001. Available at: http://www.ampainsoc.org/ce/enduring/downloads/npc/npc.pdf. Accessed May 11, 2012.
   Google Scholar
• US Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Health Statistics. Health, United States, 2006, with Chartbook on Trends in the Health of Americans. Available at: http://www. cdc.gov/nchs/data/hus/hus06.pdf. Accessed May 9, 2012.
   Google Scholar
• International Association for the Study of Pain. How prevalent is chronic pain? Pain: Clinical Updates. 2003;XI(2):1–4. Available at: http://www.iasp-pain.org/AM/AMTemplate.cfm? Section=Home&TEMPLATE=/CM/ContentDisplay.cfm& SECTION=Home&CONTENTID=7594. Accessed May 11, 2012.
   Google Scholar
• Katz NP, Adams EH, Chilcoat H, Challenges in the development of prescription opioid abuse-deterrent formulations. Clin J Pain. 2007;23:648–660.
   PubMed Web of Science ®Google Scholar
• Chou R, Fanciullo GJ, Fine PG, et al; American Pain Society–American Academy of Pain Medicine Opioids Guidelines Panel. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain. 2009;10:113–130.
   PubMed Web of Science ®Google Scholar
• Governale L. Outpatient prescription opioid utilization in the U.S., years 2000–2009. Washington, DC: U.S. Food and Drug Administration; 2010. Available at: http://www.fda.gov/ downloads/AdvisoryCommittess/CommittessMeetingMaterials/ Drugs/DrugSafetyandRiskManagementAdvisoryCommittee/ UCM220950.pdf. Accessed May 11, 2012.
   Google Scholar
• Paulozzi LJ, Kilbourne EM, Shah NG, A history of being prescribed controlled substances and risk of drug overdose death. Pain Med. 2012;13:87–95.
   PubMed Web of Science ®Google Scholar
• Chabal C, Erjavec MK, Jacobson L, Mariano A, Chaney E. Prescription opiate abuse in chronic pain patients: clinical criteria, incidence, and predictors. Clin J Pain. 1997;13:150–155.
   PubMed Web of Science ®Google Scholar
• Katz NP, Sherburne S, Beach M, Behavioral monitoring and urine toxicology testing in patients receiving long-term opioid therapy. Anesth Analg. 2003;97:1097–1102.
   PubMed Web of Science ®Google Scholar
• Manchikanti L, Pampati V, Damron KS, Fellows B, Barnhill RC, Beyer CD. Prevalence of opioid abuse in interventional pain medicine practice settings: a randomized clinical evaluation. Pain Physician. 2001;4:358–365.
   PubMedGoogle Scholar
• Fishbain DA, Cole B, Lewis J, Rosomoff HL, Rosomoff RS. What percentage of chronic nonmalignant pain patients exposed to chronic opioid analgesic therapy develop abuse/addiction and/or aberrant drug-related behaviors? A structured evidence-based review. Pain Med. 2008;9:444–459.
   PubMed Web of Science ®Google Scholar
• Substance Abuse and Mental Health Services Administration. Results From the 2010 National Survey on Drug Use and Health: Summary of National Findings. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2011. NSDUH Series H-41, HHS Publication No. (SMA) 11–4658.
   Google Scholar
• Joranson DE, Gilson AM. Drug crime is a source of abused pain medications in the United States. J Pain Symptom Manage. 2005;30:299–301.
   PubMed Web of Science ®Google Scholar
• Fass JA, Hardigan PC. Attitudes of Florida pharmacists toward implementing a state prescription drug monitoring program for controlled substances. J Manag Care Pharm. 2011;17:430–438.
   PubMed Web of Science ®Google Scholar
• Substance Abuse and Mental Health Services Administration. Drug Abuse Warning Network, 2009: National Estimates of Drug-Related Emergency Department Visits. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2011. DAWN Series D-35, HHS Publication No. (SMA) 11–4659US.
   Google Scholar
• Department of Health and Human Services, Centers for Disease Control and Prevention. Unintentional drug poisoning in the United States. July 2010. Available at: http://www. cdc.gov/HomeandRecreationalSafety/pdf/poison-issue-brief.pdf. Accessed July 11, 2012.
   Google Scholar
• US Department of Health and Human Services, Centers for Disease Control and Prevention. Policy impact: prescription painkiller overdoses. Updated December 19, 2011. Available at: http://www.cdc.gov/homeandrecreationalsafety/rxbrief. Accessed May 9, 2012.
   Google Scholar
• Wunsch MJ, Nakamoto K, Behonick G, Massello W. Opioid deaths in rural Virginia: a description of the high prevalence of accidental fatalities involving prescribed medications. Am J Addict. 2009;18:5–14.
   PubMed Web of Science ®Google Scholar
• Zacny JP, Paice JA, Coalson DW. Separate and combined psychopharmacological effects of alprazolam and oxycodone in healthy volunteers. Drug Alcohol Depend. 2012;124: 274–282.
   Google Scholar
• US Department of Health and Human Services, Centers for Disease Control and Prevention. Vital signs: overdoses of prescription opioid pain relievers—United States, 1999–2008. MMWR Morb Mortal Wkly Rep. 2011; 60:1487–1492.
   Google Scholar
• Warner M, Chen LH, Makuc DM. Increase in Fatal Poisonings Involving Opioid Analgesics in the Unites States, 1999–2006. Hyattsville, MD: National Center for Health Statistics; 2009. NCHS Data Brief No. 22. Available at: http:// www.cdc.gov/nchs/data/databriefs/db22.htm. Accessed April 19, 2012.
   Google Scholar
• The National Center on Addiction and Substance Abuse at Columbia University. Under the counter: the diversion and abuse of controlled prescription drugs in the U.S. July 2005. Available at: http://www.casacolumbia.org/templates/ Publications_Reports.aspx#r19. Accessed May 9, 2012.
   Google Scholar
• Cone ET, Fant RV, Rohay JM, Oxycodone involvement in drug abuse deaths: a DAWN-based classification scheme applied to an oxycodone postmortem database containing over 1000 cases. J Anal Toxicol. 2003;27:57–67.
   PubMed Web of Science ®Google Scholar
• Hall AJ, Logan JE, Toblin RL, Patterns of abuse among unintentional pharmaceutical overdose fatalities. JAMA. 2008;300:2613–2620.
   PubMed Web of Science ®Google Scholar
• Larance B, Degenhardt L, Lintzeris N, Winstock A, Mattick R. Definitions related to the use of pharmaceutical opioids: extramedical use, diversion, nonadherence and aberrant medication-related behaviours. Drug Alcohol Rev. 2011;30:236–245.
   PubMed Web of Science ®Google Scholar
• Savage SR, Joranson, DE, Covington EC, Schnoll SH, Heit HA, Gilson AM. Definitions related to the medical use of opioids: evolution towards universal agreement. J Pain Symptom Manage. 2003;26:655–667.
   PubMed Web of Science ®Google Scholar
• Peppin JF, Coleman JJ, Kirsh KL. Issues and critiques of the forthcoming risk evaluation and mitigation strategy (REMS) for opioids in pain management. Issues Law Med. 2011;27:91–119.
   Google Scholar
• Passik SD, Hays L, Eisner N, Kirsh KL. Psychiatric and pain characteristics of prescription drug abusers entering drug rehabilitation. J Pain Palliat Care Pharmacother. 2006;20:5–13.
   PubMedGoogle Scholar
• Surratt H, Kurtz SP, Cicero TJ. Alternate routes of administration and risk for HIV among prescription opioid abusers. J Addict Dis. 2011;30:334–341.
   PubMed Web of Science ®Google Scholar
• Goodnough A, Zezima K. Drug is harder to abuse, but users persevere. The New York Times. June 15, 2011. Available at: http://www.nytimes.com/2011/06/16/health/16oxy.html?_r=1. Accessed April 19, 2012.
   Google Scholar
• Katz N. Abuse-deterrent opioid formulations: are they a pipe dream? Curr Rheumatol Rep. 2008;10:11–18.
   PubMedGoogle Scholar
• OxyContin (oxycodone HCl controlled-release) tablets CII [package insert]. Stamford, CT: Purdue Pharma L.P.; 2010.
   Google Scholar
• Hays LR. A profile of OxyContin addiction. J Addict Dis. 2004;23:1–9.
   PubMed Web of Science ®Google Scholar
• Amabile CM, Bowman BJ. Overview of oral modified-release opioid products for the management of chronic pain. Ann Pharmacother. 2006;40:1327–1335.
   PubMed Web of Science ®Google Scholar
• Marsch LA, Bickel WK, Badger GJ, Effects of infusion rate of intravenously administered morphine on physiological, psychomotor, and self-reported measures in humans. J Pharmacol Exp Ther. 2001;299:1056–1065.
   PubMed Web of Science ®Google Scholar
• Comer SD, Ashworth JB, Sullivan MA, Vosburg SK, Saccone PA, Foltin RW. Relationship between rate of infusion and reinforcing strength of oxycodone in humans. J Opioid Manag. 2009;5:203–212.
   PubMedGoogle Scholar
• de Wit H, Dudish S, Ambre J. Subjective and behavioral effects of diazepam depend on its rate of onset. Psychopharmacology (Berl). 1993;112:324–330.
   PubMed Web of Science ®Google Scholar
• Mumford GK, Evans SM, Fleishaker JC, Griffiths RR. Alprazolam absorption kinetics affects abuse liability. Clin Pharmacol Ther. 1995;57:356–365.
   PubMed Web of Science ®Google Scholar
• Jayawant SS, Balkrishnan R. The controversy surrounding OxyContin abuse: issues and solutions. Ther Clin Risk Manag. 2005;1:77–82.
   PubMedGoogle Scholar
• Katz N, Fernandez K, Chang A, Benoit C, Butler SF. Internet-based survey of nonmedical prescription opioid use in the United States. Clin J Pain. 2008;24:528–535.
   PubMed Web of Science ®Google Scholar
• Carise D, Dugosh KL, McLellan AT, Camilleri A, Woody GE, Lynch KG. Prescription OxyContin abuse among patients entering addiction treatment. Am J Psychiatry. 2007;164:1750–1756.
   PubMed Web of Science ®Google Scholar
• McCabe SE, Cranford JA, Boyd CJ, Teter CJ. Motives, diversion and routes of administration associated with nonmedical use of prescription opioids. Addict Behav. 2007;32:562–575.
   PubMed Web of Science ®Google Scholar
• Butler SF, Black RA, Serrano JM, Wood ME, Budman SH. Characteristics of prescription opioid abusers in treatment: prescription opioid use history, age, use patterns, and functional severity. J Opioid Manag. 2010;6:239–241, 246–252.
   PubMedGoogle Scholar
• Butler SF, Fernandez KC, Chang A, Measuring attractiveness for abuse of prescription opioids. Pain Med. 2010;11:67–80.
   PubMed Web of Science ®Google Scholar
• Back SE, Lawson KM, Singleton LM, Brady KT. Characteristics and correlates of men and women with prescription opioid dependence. Addict Behav. 2011;36:829–834.
   PubMed Web of Science ®Google Scholar
• Young AM, Havens JR, Leukefeld CG. Route of administration for illicit prescription opioids: a comparison of rural and urban drug users. Harm Reduct J. 2010;7:24–31.
   PubMed Web of Science ®Google Scholar
• Lankenau SE, Teti M, Silva K, Bloom JJ, Harocopos A, Treese M. Initiation into prescription opioid misuse amongst young injection drug users. Int J Drug Policy. 2012;23:37–44.
   PubMed Web of Science ®Google Scholar
• Webster LR, Bath B, Medve RA. Opioid formulations in development designed to curtail abuse: who is the target? Expert Opin Investig Drugs. 2009;18:255–263.
   PubMed Web of Science ®Google Scholar
• Shram MJ, Sathyan G, Khanna S, Evaluation of the abuse potential of extended release hydromorphone versus immediate release hydromorphone. J Clin Psychopharmacol. 2010;30:25–33.
   PubMed Web of Science ®Google Scholar
• Exalgo (hydromorphone HCl) extended-release tablets, CII [package insert]. Hazelwood, MO: Mallinckrodt Brand Pharmaceuticals, Inc.; 2010.
   Google Scholar
• Gupta S, Sathyan G. Providing constant analgesia with OROS® hydromorphone. J Pain Symptom Manage. 2007;33(2S):S19–S24.
   Google Scholar
• Concerta (methylphenidate HCl) extended-release tablets CII [package insert]. Fort Washington, PA: Specialty Pharmaceuticals Division of McNeil-PPC, Inc.; 2006.
   Google Scholar
• Parasrampuria DA, Schoedel KA, Schuller R, Do formulation differences alter abuse liability of methylphenidate? A placebo-controlled, randomized, double-blind, crossover study in recreational drug users. J Clin Psychopharmacol. 2007;27:459–467.
   PubMed Web of Science ®Google Scholar
• Spencer TJ, Biederman J, Ciccone PE, PET study examining pharmacokinetics, detection and likeability, and dopamine transporter receptor occupancy of short- and long-acting oral methylphenidate. Am J Psychiatry. 2006;163:387–395.
   PubMed Web of Science ®Google Scholar
• Bright GM. Abuse of medications employed for the treatment of ADHD: results from a large-scale community survey. Medscape J Med. 2008;10:111–117.
   PubMedGoogle Scholar
• FDA complete response letter received or Remoxy [press release]. New York, NY: Pfizer Inc. June 24, 2011. Available at: http://www.pfizer.com/news/press_releases/pfizer_press_release. jsp?guid=20110624005389en&source=RSS_2011&page=11. Accessed May 9, 2012.
   Google Scholar
• Setnik B, Roland CL, Cleveland JM, Webster L. The abuse potential of Remoxy®, an extended-release formulation of oxycodone, compared with immediate- and extended-release oxycodone. Pain Med. 2011;12:618–631.
   PubMed Web of Science ®Google Scholar
• Compton WM, Volkow ND. Abuse of prescription drugs and the risk of addiction. Drug Alcohol Depend. 2006;83(Suppl 1):S4–S7.
   PubMed Web of Science ®Google Scholar
• Schneider JP, Matthews M, Jamison RN. Abuse-deterrent and tamper-resistant opioid formulations: what is their role in addressing prescription opioid abuse? CNS Drugs. 2010;24:805–810.
   PubMed Web of Science ®Google Scholar
• Webster L, St Marie B, McCarberg B, Passik SD, Panchal SJ, Voth E. Current status and evolving role of abuse-deterrent opioids in managing patients with chronic pain. J Opioid Manag. 2011;7:235–245.
   PubMedGoogle Scholar
• Bartholomaeus JH, Arkenau-Maric E, Galia E. Opioid extended-release tablets with improved tamper-resistant properties. Expert Opin Drug Deliv. 2012 Jun 13 [Epub ahead of print].
   Google Scholar
• Ultram (tramadol HCl) extended-release tablets [package insert]. Raritan, NJ: PriCara, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc.; 2009.
   Google Scholar
• Opana ER (oxymorphone hydrochloride) extended-release tablets, CII [package insert]. Chadds Ford, PA: Endo Pharmaceuticals Inc.; 2012.
   Google Scholar
• Oxecta (oxycodone hydrochloride) tablets for oral use, CII [package insert]. Bristol, TN: King Pharmaceuticals; 2011.
   Google Scholar
• Embeda (morphine sulphate and naloxone hydrochloride) extended-release capsules for oral use, CII [package insert]. New York, NY: Pfizer; 2010.
   Google Scholar
• EMBEDA. Important information for patients and prescribers. Available at: http://www.embeda.com. Accessed July 12, 2012.
   Google Scholar
• Acura Pharmaceuticals and King Pharmaceuticals provide update on FDA Advisory Committee meeting for Acurox® [press release]. Palatine, IL, and Bristol, TN: Acura Pharmaceuticals and King Pharmaceuticals. April 22, 2010. Available at: http://acurapharm.com/investors/press-releases/. Accessed May 9, 2012.
   Google Scholar
• Collegium Pharmaceutical announces series b financing and advancement of development program for its DETERx tamper-resistant, extended-release opioid [press release]. Cumberland, RI: Collegium Pharmaceutical. February 22, 2012. Available at: http://www.collegiumpharma.com/press-releases/53-february-22–2012-collegium-pharmaceutical-announces-series-b-financing-and-advancement-of-development-program-for-its-deterxr-tamper-resistant-extended-release-opioid-. Accessed May 9, 2012.
   Google Scholar
• Product pipeline. Elite Pharmaceuticals, Inc. Web site. Available at: http://www.elitepharma.com/product_pipeline.asp. Accessed May 9, 2012.
   Google Scholar
• KemPharm, Inc. focuses on advanced pain management franchise [press release]. Iowa City, IA: KemPharm, Inc. May 22, 2012. Available at: http://www.kempharm.com/pdf/ KP_PR_052212.pdf. Accessed July 12, 2012.
   Google Scholar
• Probuphine. Titan Pharmaceuticals, Inc., Web site. Available at: http://www.titanpharm.com/products.htm#gpm1_2. Accessed May 9, 2012.
   Google Scholar
• Coleman JJ, Schuster CR, DuPont RL. Reducing the abuse potential of controlled substances. Pharmaceut Med. 2010;24:21–36.
   Google Scholar
• Pande P, Hines JW, Brogan AP. Tamper-resistant properties of once-daily hydromorphone ER (OROS hydromorphone ER) [abstract]. J Pain. 2011;12(4 Suppl):P58. Poster presented at American Pain Society 30th Annual Scientific Meeting; May 19–21, 2011; Austin, TX.
   Google Scholar
• Black RA, Coplan P, Cassidy TA, Chilcoat H, Budman S, Landau C, Butler SA. Effects of reformulated OxyContin® among patients assessed for substance abuse treatment in the NAVIPPRO sentinel surveillance network [abstract]. J Pain. 2012;13 (4 Suppl):S58.
   Google Scholar
• Talwin Nx Civ (pentazocine and naloxone hydrochlorides, USP) [package insert]. Bridgewater, NJ: sanofi-aventis U.S. LLC; 2008.
   Google Scholar
• Vyvanse (lisdexamfetamine dimesylate) capsules for oral use, CII [package insert]. Wayne, PA: Shire US Inc.; 2012.
   Google Scholar
• Bianchi RP. Comparison of fentanyl extraction from two different transdermal patches. J Forensic Sci. 2006;51:939–940.
   Google Scholar
• Joint Meeting of the Anesthetic and Life Support Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee; 2010. Available at: http://www.fda. gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ AnestheticAndAnalgesicDrugProductsAdvisoryCommittee/ ucm217507.htm. Accessed June 5, 2012.
   Google Scholar
• Craig DS. The Food and Drug Administration risk evaluation and mitigation strategy. J Pain Palliat Care Pharmacother. 2010;24:145–148.
   PubMedGoogle Scholar
• US Food and Drug Administration. FDA introduces new safety measures for extended-release and long-acting opioid medications. Available at: http://www.fda.gov/NewsEvents/Newsroom/ PressAnnouncements/ucm310870.htm. Accessed July 9, 2012.
   Google Scholar
• Executive Office of the President, Office of National Drug Control Policy. Epidemic: responding to America's prescription drug abuse crisis. Washington, DC: Executive Office of the President of the United States; 2011. Available at: http://www.whitehouse.gov/sites/default/files/ondcp/policy-and-research/rx_abuse_plan.pdf. Accessed May 9, 2012.
   Google Scholar